442 related articles for article (PubMed ID: 8554908)
1. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O
AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1107-13. PubMed ID: 8554908
[TBL] [Abstract][Full Text] [Related]
2. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination.
Flynn JN; Keating P; Hosie MJ; Mackett M; Stephens EB; Beatty JA; Neil JC; Jarrett O
J Immunol; 1996 Oct; 157(8):3658-65. PubMed ID: 8871667
[TBL] [Abstract][Full Text] [Related]
3. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
[TBL] [Abstract][Full Text] [Related]
4. Induction of feline immunodeficiency virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide.
Flynn JN; Cannon CA; Beatty JA; Mackett M; Rigby MA; Neil JC; Jarrett C
J Virol; 1994 Sep; 68(9):5835-44. PubMed ID: 8057464
[TBL] [Abstract][Full Text] [Related]
5. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
[TBL] [Abstract][Full Text] [Related]
6. A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction.
Beatty JA; Willett BJ; Gault EA; Jarrett O
J Virol; 1996 Sep; 70(9):6199-206. PubMed ID: 8709246
[TBL] [Abstract][Full Text] [Related]
7. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA.
Lockridge KM; Chien M; Dean GA; Stefano Cole K; Montelaro RC; Luciw PA; Sparger EE
Virology; 2000 Jul; 273(1):67-79. PubMed ID: 10891409
[TBL] [Abstract][Full Text] [Related]
8. Peptide mapping of feline immunodeficiency virus by IFN-gamma ELISPOT.
Dean GA; LaVoy A; Burkhard MJ
Vet Immunol Immunopathol; 2004 Jul; 100(1-2):49-59. PubMed ID: 15182995
[TBL] [Abstract][Full Text] [Related]
9. Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain.
Flynn JN; Cannon CA; Reid G; Rigby MA; Neil JC; Jarrett O
Immunology; 1995 Jun; 85(2):171-5. PubMed ID: 7543872
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.
Flynn JN; Cannon CA; Neil JC; Jarrett O
J Virol; 1997 Oct; 71(10):7586-92. PubMed ID: 9311839
[TBL] [Abstract][Full Text] [Related]
11. Retroviral vector-transduced cells expressing the core polyprotein induce feline immunodeficiency virus-specific cytotoxic T-lymphocytes from infected cats.
Li J; Brown WC; Song W; Carpino MR; Wolf AM; Grant CK; Elder JH; Collisson EW
Virus Res; 1995 Oct; 38(2-3):93-109. PubMed ID: 8578869
[TBL] [Abstract][Full Text] [Related]
12. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.
Lombardi S; Garzelli C; Pistello M; Massi C; Matteucci D; Baldinotti F; Cammarota G; da Prato L; Bandecchi P; Tozzini F
J Virol; 1994 Dec; 68(12):8374-9. PubMed ID: 7966629
[TBL] [Abstract][Full Text] [Related]
13. DNA vaccination using expression vectors carrying FIV structural genes induces immune response against feline immunodeficiency virus.
Cuisinier AM; Mallet V; Meyer A; Caldora C; Aubert A
Vaccine; 1997 Jul; 15(10):1085-94. PubMed ID: 9269051
[TBL] [Abstract][Full Text] [Related]
14. FIV vaccine studies. I. Immune response to recombinant FIV env gene products and outcome after challenge infection.
Lutz H; Hofmann-Lehmann R; Bauer-Pham K; Holznagel E; Tozzini F; Bendinelli M; Reubel G; Aubert A; Davis D; Cox D
Vet Immunol Immunopathol; 1995 May; 46(1-2):103-13. PubMed ID: 7618250
[TBL] [Abstract][Full Text] [Related]
15. Feline immunodeficiency virus Gag- and Env-specific immune responses after vaginal versus intravenous infection.
Burkhard MJ; Mathiason CK; Bowdre T; Hoover EA
AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1767-78. PubMed ID: 11788028
[TBL] [Abstract][Full Text] [Related]
16. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression.
Boretti FS; Leutenegger CM; Mislin C; Hofmann-Lehmann R; König S; Schroff M; Junghans C; Fehr D; Huettner SW; Habel A; Flynn JN; Aubert A; Pedersen NC; Wittig B; Lutz H
AIDS; 2000 Aug; 14(12):1749-57. PubMed ID: 10985311
[TBL] [Abstract][Full Text] [Related]
17. Differences in Env and Gag protein expression patterns and epitope availability in feline immunodeficiency virus infected PBMC compared to infected and transfected feline model cell lines.
Roukaerts IDM; Grant CK; Theuns S; Christiaens I; Acar DD; Van Bockstael S; Desmarets LMB; Nauwynck HJ
Virus Res; 2017 Jan; 227():249-260. PubMed ID: 27836726
[TBL] [Abstract][Full Text] [Related]
18. Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus.
Stevens R; Howard KE; Nordone S; Burkhard M; Dean GA
J Virol; 2004 Aug; 78(15):8210-8. PubMed ID: 15254192
[TBL] [Abstract][Full Text] [Related]
19. Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS.
Klonjkowski B; Klein D; Galea S; Gavard F; Monteil M; Duarte L; Fournier A; Sayon S; Górna K; Ertl R; Cordonnier N; Sonigo P; Eloit M; Richardson J
Vaccine; 2009 Feb; 27(6):928-39. PubMed ID: 19070641
[TBL] [Abstract][Full Text] [Related]
20. Utilization of Feline ELISpot to Evaluate the Immunogenicity of a T Cell-Based FIV MAP Vaccine.
Sahay B; Aranyos AM; McAvoy A; Yamamoto JK
Methods Mol Biol; 2018; 1808():197-219. PubMed ID: 29956186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
